Xingwang Xie

1.4k total citations
42 papers, 1.1k citations indexed

About

Xingwang Xie is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Xingwang Xie has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Oncology and 14 papers in Immunology. Recurrent topics in Xingwang Xie's work include Hepatitis B Virus Studies (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immune Cell Function and Interaction (7 papers). Xingwang Xie is often cited by papers focused on Hepatitis B Virus Studies (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immune Cell Function and Interaction (7 papers). Xingwang Xie collaborates with scholars based in China. Xingwang Xie's co-authors include Hongsong Chen, Lai Wei, Ran Fei, Henghui Zhang, Xueyan Wang, Gaixia He, Jinxue Zhou, Yanhui Chen, Hui Zeng and Yaxian Kong and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Xingwang Xie

40 papers receiving 1.1k citations

Peers

Xingwang Xie
Xiaofeng Han China
Benjamin Ruf United States
Huafeng Wang China
Mairene Coto‐Llerena Switzerland
Karen Man‐Fong Sze Hong Kong
Xing Gu China
Zhihua Ruan China
Xiaojun Zhu China
Caecilia Sukowati Italy
Yajin Chen China
Xiaofeng Han China
Xingwang Xie
Citations per year, relative to Xingwang Xie Xingwang Xie (= 1×) peers Xiaofeng Han

Countries citing papers authored by Xingwang Xie

Since Specialization
Citations

This map shows the geographic impact of Xingwang Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingwang Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingwang Xie more than expected).

Fields of papers citing papers by Xingwang Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingwang Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingwang Xie. The network helps show where Xingwang Xie may publish in the future.

Co-authorship network of co-authors of Xingwang Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Xingwang Xie. A scholar is included among the top collaborators of Xingwang Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingwang Xie. Xingwang Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Meiling, Ning Xie, Chunxia Wu, et al.. (2025). Novel nanoparticle-combined therapy through EGFR and PD-L1 blockade: PFPR-siRNA-mediated suppressing NSCLC proliferation via PDT and enhanced antitumor immunity. Colloids and Surfaces B Biointerfaces. 259. 115284–115284.
2.
3.
4.
Ma, Peiwen, Yale Jiang, Zhao Guo, et al.. (2024). Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review. European Journal of Cancer. 209. 114224–114224. 6 indexed citations
5.
Tai, Sheng, et al.. (2022). Primary duodenal papilla lymphoma producing obstructive jaundice: a case report. BMC Surgery. 22(1). 110–110. 3 indexed citations
6.
Zhou, Hongjian, et al.. (2021). Zinc finger protein 852 is essential for the proliferation, drug sensitivity, and self‐renewal of gastric cancer cells. Cell Biology International. 46(4). 579–587. 3 indexed citations
7.
Zhou, Hongjian, et al.. (2020). NKp46+ lamina propria natural killer cells undergo metabolic reprogramming in a mouse experimental colitis model. Inflammation Research. 69(4). 401–414. 2 indexed citations
8.
Zhao, Wensi, Wanpu Yan, Dongbo Chen, et al.. (2019). Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma.. PubMed Central. 9(6). 1183–1200. 24 indexed citations
9.
Chen, Dongbo, Yangjing Zhao, Xueyan Wang, et al.. (2019). Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis. Chinese Medical Journal. 132(13). 1572–1581. 19 indexed citations
10.
Zhao, Yangjing, Yanhui Chen, Ying Hu, et al.. (2018). Genomic alterations across six hepatocellular carcinoma cell lines by panel-based sequencing. Translational Cancer Research. 7(2). 231–239. 5 indexed citations
11.
Xie, Xingwang, Xueyan Wang, Dong Jiang, et al.. (2017). PPPDE1 is a novel deubiquitinase belonging to a cysteine isopeptidase family. Biochemical and Biophysical Research Communications. 488(2). 291–296. 18 indexed citations
12.
Zhao, Yangjing, Xingwang Xie, Weijia Liao, et al.. (2016). The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma. Oncology Reports. 37(1). 289–296. 25 indexed citations
13.
Liu, Ruyu, Huiying Rao, Dong Jiang, et al.. (2015). Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection. PLoS ONE. 10(9). e0138756–e0138756. 8 indexed citations
14.
Wang, Ye, Huiying Rao, Xingwang Xie, & Lai Wei. (2015). Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus. Chinese Medical Journal. 128(19). 2625–2631. 10 indexed citations
15.
He, Gaixia, Henghui Zhang, Jinxue Zhou, et al.. (2015). Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 34(1). 141–141. 217 indexed citations
16.
Yan, Linlin, Henghui Zhang, Hui Ma, et al.. (2015). Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. Scientific Reports. 5(1). 17950–17950. 16 indexed citations
17.
Ma, Hui, Xingliang Zhao, Xueyan Wang, et al.. (2013). 2’,3’-Cyclic Nucleotide 3’-Phosphodiesterases Inhibit Hepatitis B Virus Replication. PLoS ONE. 8(11). e80769–e80769. 7 indexed citations
18.
Liu, Ruyu, Huiying Rao, Jianghua Wang, et al.. (2013). Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313–327 and 432–443 of Hepatitis C Virus E1E2 Glycoproteins. PLoS ONE. 8(6). e66872–e66872. 6 indexed citations
19.
Chen, Yanhui, Weijia Liao, Jinxue Zhou, et al.. (2013). FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. Journal of Experimental & Clinical Cancer Research. 32(1). 39–39. 34 indexed citations
20.
Wang, Yan, Henghui Zhang, Yanhui Chen, et al.. (2012). [Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma].. PubMed. 46(6). 527–32. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaofeng Han Breakdown of academic impact, for papers by Benjamin Ruf Breakdown of academic impact, for papers by Huafeng Wang Breakdown of academic impact, for papers by Mairene Coto‐Llerena Breakdown of academic impact, for papers by Karen Man‐Fong Sze Breakdown of academic impact, for papers by Xing Gu Breakdown of academic impact, for papers by Zhihua Ruan Breakdown of academic impact, for papers by Xiaojun Zhu Breakdown of academic impact, for papers by Caecilia Sukowati Breakdown of academic impact, for papers by Yajin Chen
Rankless by CCL
2026